Balanced View on INOVIO’s INO-3107: Strong Long-Term Data Offset by Regulatory and Timing Uncertainty Driving Hold Rating

Analyst Ram Selvaraju of H.C. Wainwright maintains a Hold rating on Inovio Pharmaceuticals with a price target of $3.00. He cites regulatory uncertainties and the FDA's standard review of INO-3107 as key factors. While the drug shows promise with long-term clinical data and Orphan Drug and Breakthrough Therapy designations, the PDUFA date is set for late 2026, leading to a balanced risk-reward assessment. Selvaraju has a 25.1% average return and a 56.71% success rate on his stock recommendations.